Sutro Biopharma, Inc. Overview
Pro stress-test →Sutro is advancing a cutting-edge, next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro's cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types.
Strategic Profile
Pro stress-test →Sutro is an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), with STRO-006, a differentiated integrin beta-6 ADC expected to enter clinical development in 2026 aimed at multiple solid tumors, and ongoing collaborations with Ipsen for STRO-003, a ROR1 ADC, and with Astellas for dual-payload immunostimulatory ADCs (iADCs).
Competitive Landscape
Pro stress-test →Mersana Therapeutics, Inhibrx, Fate Therapeutics, Arcus Biosciences, and Iovance Biotherapeutics are among the 117 competitors of Sutro Biopharma, with competition in the broader ADC and oncology immunotherapy space intensifying. Sutro's differentiation lies in its cell-free protein synthesis platform (XpressCF) enabling dual-payload ADC design capabilities.
Industry Context
Sutro Biopharma, Inc. operates in Oncology Biotechnology / Antibody-Drug Conjugates (ADCs).
Key facts
Founded: 2003 · Headquarters: South San Francisco, United States · Employees: 130 · Revenue: $106M · Market cap: $256M